(4-氨基-5-氯-2-甲氧基)-n-(3-甲氧基(4-哌啶))苯甲酰胺 | 84946-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氨基-5-氯-2-甲氧基)-n-(3-甲氧基(4-哌啶))苯甲酰胺
• 中文别名: (4-氨基-5-氯-2-甲氧基)-N-[3-甲氧基(4-哌啶基)]苯甲酰胺
• 英文名称: cis-4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide
• 英文别名: norcisapride；cis-norcisapride；cis-4-amino-5-chloro-2-methoxy-N-(3-methoxy-piperidin-4-yl)benzamide；4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide
• CAS: 84946-16-7
• 化学式: C₁₄H₂₀ClN₃O₃
• 分子量: 313.784
• InChiKey: OMLDMGPCWMBPAN-UHFFFAOYSA-N

物化性质

• 熔点：
  190-193 °C(lit.)
• 沸点：
  461.0±45.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  常温常压下稳定

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  85.6
• 氢给体数：
  3
• 氢受体数：
  5

ADMET

代谢

Norcisapride 是已知的人体内代谢物，来源于 (+-)-Cisapride。

Norcisapride is a known human metabolite of (+-)-Cisapride.

来源:NORMAN Suspect List Exchange

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 储存条件：
  保持贮藏器密封，并将其存放在阴凉、干燥处。确保工作间有良好的通风或排气装置。

反应信息

• 作为反应物：
  描述：

  (4-氨基-5-氯-2-甲氧基)-n-(3-甲氧基(4-哌啶))苯甲酰胺 生成 (+)-norcisapride DBT salt
  参考文献：
  名称：

  WO20070149929A1

  摘要：

  公开号：
• 作为产物：
  描述：

  3,4,4-三甲氧基哌啶-1-羧酸乙酯 在 硫酸 、 ammonium acetate 、 sodium cyanoborohydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 14.25h， 生成 (4-氨基-5-氯-2-甲氧基)-n-(3-甲氧基(4-哌啶))苯甲酰胺
  参考文献：
  名称：

  Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent

  摘要：

  A series of novel benzamide derivatives, altering the 4-fluorophenylalkyl moiety in cisapride, were synthesized as 5-HT4 receptor agonists, and SAR of these analogs was examined on in vitro and in vivo prokinetic activities. These compounds were synthesized for high 5-HT4 receptor binding affinities and low hERG affinities. Several types of analogs were obtained and screened for 5-HT4 binding, hERG blocking, agonism, and gastric emptying assessment. Among the analogues, compound 23g showed promising results compared with the other analogs with respect to gastric emptying rates in rats. Therefore, we suggest that it may be a clinical candidate for the development of a potent prokinetic agent to treat GI disorders. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.006

文献信息

• Substituted N-(3-hydroxy-4-piperidinyl)benzamides as gastrointestinal
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04906643A1

  公开（公告）日：1990-03-06

  N-(3-hydroxy-4-piperidinyl)substituted benzamides, their N-oxide forms and pharmaceutically acceptable acid-addition salts having gastrointestinal motility stimulating properties, compositions containing the same, and methods of treating warm blooded animals suffering from a decreased peristalsis of the gastrointestinal system.

  N-(3-羟基-4-哌啶基)取代苯甲酰胺，其N-氧化物形式和具有胃肠动力促进作用的药用可接受的酸盐，含有这些化合物的组合物，以及治疗患有胃肠系统蠕动减弱的温血动物的方法。
• 4-(aroylamino)piperidine-butanimide derivatives
  申请人：Janssen Pharmaceutica

  公开号：US04990521A1

  公开（公告）日：1991-02-05

  A method of treating warm-blooded animals suffering from diarrhea, which method comprises the administration of particular 4-(aroylamino)piperidinebutanamide derivatives and compositions containing the same. Novel 4-(aroylamino)piperidinebutanamide derivatives.

  一种治疗患有腹泻的温血动物的方法，该方法包括给予特定的4-(芳酰氨基)哌啶丁酰胺衍生物和包含相同成分的制剂。新型的4-(芳酰氨基)哌啶丁酰胺衍生物。
• Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
  申请人：Janssen Pharmaceutical N.V.

  公开号：US04975439A1

  公开（公告）日：1990-12-04

  Substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides, their N-oxide forms, their pharmaceutically acceptable acid addition salts and stereochemically isomeric forms having gastrointestinal motility stimulating properties, compositions containing the same, and methods of treating warm-blooded animals suffering from motility disorders of the gastrointestinal system.

  取代N-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺，其N-氧化物形式，其药用可接受的酸盐和具有促进胃肠蠕动性能的立体化异构体形式，含有这些物质的组合物，以及治疗患有胃肠系统蠕动障碍的温血动物的方法。
• NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF
  申请人：Yoo Moo-Hi

  公开号：US20100105727A1

  公开（公告）日：2010-04-29

  The present invention provides a novel benzamide derivative represented by formula 1 and an isomer, a pharmaceutically acceptable salt or hydrate thereof, and a composition for activating a 5-HT4 receptor comprising the same, as an active ingredient. Benzamide derivatives of the present invention has superior affinity for 5-HT4 receptors, capability to reduce the gastric evacuation time, capability to alleviate ventricular tachycardia, ventricular fibrillation, torsades de pointes and QT prolongation, and low toxicity. Therefore, benzamide derivatives of the present invention are therapeutically effective for digestive system diseases.

  本发明提供了一种新颖的苯甲酰胺衍生物，其由式1表示，以及一个异构体，其药学上可接受的盐或水合物，以及包含相同物质的用于激活5-HT4受体的组合物，作为活性成分。本发明的苯甲酰胺衍生物具有优越的亲和力，能够减少胃排空时间，能够缓解室性心动过速、室颤、扭转型室性心动过速和QT间期延长，并且毒性低。因此，本发明的苯甲酰胺衍生物在治疗消化系统疾病方面具有治疗效果。
• [EN] STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS<br/>[FR] COMPOSES STEREO-ISOMERES ET METHODES DE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX ET DU SYSTEME NERVEUX CENTRAL
  申请人：ARYX THERAPEUTICS

  公开号：WO2005068461A1

  公开（公告）日：2005-07-28

  The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.

  本发明提供了式（X）的立体异构化合物：其中变量如本文所定义，并提供了用于安全有效治疗各种胃肠道疾病的组合物，包括但不限于胃轻瘫、胃食管反流及相关症状。本发明的化合物还可用于治疗涉及中枢神经系统的各种疾病。